Home Medizin Eine kostengünstige Zweitlinienbehandlung für rezidiviertes/refraktäres DLBCL

Eine kostengünstige Zweitlinienbehandlung für rezidiviertes/refraktäres DLBCL

von NFI Redaktion

A newly published study reports that Lisocabtagene maraleucel (liso-cel), a CAR-T cell therapy, is a cost-effective second-line treatment for relapsed and refractory (difficult to treat) diffuse large B-cell lymphoma (r/r DLBCL). The study, published in Blood Advances, is the first of its kind to include health care expenditures, societal productivity losses, and patient quality of life in the assessment of the drug’s cost-effectiveness.

„Our study considered the often overlooked societal costs associated with cancer treatment, which are usually neglected in cost-effectiveness analyses that focus solely on healthcare expenditures. Cancer treatments can impact the quality of life and lead to work absences and challenges in coping with daily activities, particularly in older individuals. Treatments that improve quality of life not only benefit the patient, but also reduce these common societal costs, which is an important aspect of our cost-effectiveness evaluation.“

Mohamed Abou-el-Enein, MD, PhD, MSPH, Associate Professor of Medicine at the Keck School of Medicine of the University of Southern California and lead author of the study

DLBCL, the most common form of non-Hodgkin lymphoma, is a cancer that affects lymphocytes, a type of white blood cell. In cases where DLBCL does not respond to initial treatment or reoccurs within 12 months of completing treatment, the standard treatment protocol typically includes platinum-based chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation. In 2022, the U.S. Food and Drug Administration (FDA) approved Liso-Cel as a second-line treatment for DLBCL. However, the cost-effectiveness of Liso-Cel is currently a topic of discussion among oncologists, especially given the high price of the drug, which increased from $410,300 to $447,227 between 2022 and 2023.

In this study, researchers conducted a cost-effectiveness analysis of Liso-Cel for the treatment of r/r DLBCL using a partitioned survival model, a common economic tool for evaluating medical treatments at different stages of disease progression. They found that patients treated with Liso-Cel had an average life expectancy of 5.34 years and gained 3.64 quality-adjusted life years (QALYs), compared to 2.47 years and 1.62 QALYs with standard care (SC). The cost-effectiveness of Liso-Cel, measured by the incremental cost-effectiveness ratio (ICER), was $99,669 per QALY from a healthcare sector perspective and $68,212 per QALY from a societal perspective. The ICER assesses the additional costs required for each gained QALY, assuming a societal willingness to pay of up to $100,000 per QALY. These figures indicate that Liso-Cel is a cost-effective treatment and falls below the threshold of $100,000 per QALY.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.